Analysts at Numis Securities Ltd started coverage on shares of Allergy Therapeutics plc (LON:AGY) in a research note issued to investors on Wednesday. The brokerage set a “buy” rating and a GBX 37 ($0.48) price target on the stock. Numis Securities Ltd’s price objective indicates a potential upside of 101.36% from the stock’s previous close.
A number of other brokerages also recently issued reports on AGY. Panmure Gordon reaffirmed a “buy” rating and issued a GBX 53 ($0.69) price target on shares of Allergy Therapeutics plc in a report on Friday, June 10th. Stifel Nicolaus reaffirmed a “buy” rating and issued a GBX 72 ($0.94) price target on shares of Allergy Therapeutics plc in a report on Friday, July 8th.
Shares of Allergy Therapeutics plc (LON:AGY) opened at 18.375 on Wednesday. The firm’s market cap is GBX 102.81 million. Allergy Therapeutics plc has a 1-year low of GBX 18.00 and a 1-year high of GBX 34.82. The company has a 50-day moving average of GBX 18.79 and a 200-day moving average of GBX 22.72.
Allergy Therapeutics plc Company Profile
Allergy Therapeutics Plc is a United Kingdom-based pharmaceutical company. The Company focuses on the treatment and prevention of allergy with aluminum free products. It provides information to healthcare professionals about the prevention, diagnosis and treatment of allergic conditions with focus on allergy vaccination, which is also known as specific immunotherapy or desensitization therapy.
Receive News & Ratings for Allergy Therapeutics plc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Allergy Therapeutics plc and related companies with MarketBeat.com's FREE daily email newsletter.